Mode of Action
Our proprietary small molecules inhibit the expression and function of flagella. These bacterial ‘tails’ are required for swarming, adhesion, and invasion. The bacteria are therefore unable to establish an infection.
Swarming also plays a key role during sepsis, helping the bacteria to invade and colonise other organs beyond the original site of infection.
Without their full weapons arsenal of virulence factors, the body’s immune system is more able to clear infections and antibiotics have a more potent effect on the bacteria, reducing antimicrobial resistance.
Prophylactic treatment
High-risk patients (e.g., burns)
Screened for colonisation as standard-of-care
Patient selection (positive colonisation)
Antibiotic-SPARING
Combination treatment with antibiotics
Acute infection (e.g., bacteraemia)
Antibiotic-ENHANCING
Clinical Use
Targeting swarming has two clinical use cases:
Prophylactic monotherapy in patients at high risk of a P. aeruginosa infection
Combination treatment for patients with acute P. aeruginosa infections
Swarming is critical in the early stages of the infection pathophysiology, meaning our product is a first-line treatment option. Current standard-of-care is combination treatment for acute infections and our first-in-class mechanism gives physicians an antibiotic-sparing and antibiotic-enhancing treatment option